Skip to main content

Enterin raises another $5.7 million to advance potential Parkinson's therapy

The company is aiming to be the first to develop a drug that repairs dysfunction in the gut-brain axis in patients with neurodegenerative diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.